Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.

ABSTRACT: Despite important advances in the treatment of metastatic melanoma with the development of MAPK-targeted agents and immune checkpoint inhibitors, the majority of patients either do not respond to therapies or develop acquired resistance. Furthermore, there is no effective targeted therapy currently available for BRAF wild-type melanomas (approximately 50% of cutaneous melanoma). Thus, there is a compelling need for new efficient targeted therapies. Prohibitins (PHBs) are overexpressed in several types of cancers and implicated in the regulation of signaling networks that promote cell invasion and resistance to cell apoptosis. Herein, we show that PHBs are highly expressed in melanoma and are associated with not only poor survival but also with resistance to BRAFi/MEKi. We designed and iden

SUBMITTER: Najem A 

PROVIDER: S-EPMC10378173 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature